Citadel Advisors
AQST icon

Citadel Advisors’s Aquestive Therapeutics AQST Stock Holding History

Citadel Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.36M Buy
328,200
+82,400
+34% +$334K ﹤0.01% 6944
2025
Q4 		$1.59M Buy
245,800
+181,600
+283% +$1.13M ﹤0.01% 6384
2025
Q3 		$359K Buy
64,200
+48,800
+317% +$211K ﹤0.01% 9938
2025
Q2 		$51K Buy
15,400
+15,000
+3,750% +$43K ﹤0.01% 11758
2025
Q1 		$1.16K Sell
400
-17,400
-98% -$52.7K ﹤0.01% 14160
2024
Q4 		$63.4K Sell
17,800
-57,300
-76% -$264K ﹤0.01% 12118
2024
Q3 		$374K Buy
75,100
+13,700
+22% +$53.3K ﹤0.01% 8856
2024
Q2 		$160K Buy
61,400
+27,900
+83% +$93.2K ﹤0.01% 10246
2024
Q1 		$143K Buy
33,500
+17,100
+104% +$56.9K ﹤0.01% 10833
2023
Q4 		$33.1K Sell
16,400
-2,300
-12% -$4.06K ﹤0.01% 12187
2023
Q3 		$28.6K Buy
18,700
+10,200
+120% +$17.5K ﹤0.01% 12310
2023
Q2 		$14K Sell
8,500
-9,100
-52% -$16.5K ﹤0.01% 13016
2023
Q1 		$20.1K Sell
17,600
-32,600
-65% -$28.3K ﹤0.01% 13070
2022
Q4 		$45.3K Buy
+50,200
New +$47.1K ﹤0.01% 12253
2022
Q3 		– Sell
-51,300
Closed -$33K – 12547
2022
Q2 		$33K Buy
51,300
+37,300
+266% +$49.6K ﹤0.01% 12167
2022
Q1 		$37K Sell
14,000
-41,000
-75% -$120K ﹤0.01% 12984
2021
Q4 		$214K Sell
55,000
-21,700
-28% -$109K ﹤0.01% 11707
2021
Q3 		$334K Buy
76,700
+18,900
+33% +$74.1K ﹤0.01% 10821
2021
Q2 		$229K Buy
57,800
+15,900
+38% +$63.5K ﹤0.01% 11862
2021
Q1 		$218K Buy
41,900
+27,600
+193% +$147K ﹤0.01% 11525
2020
Q4 		$77K Sell
14,300
-11,200
-44% -$67.1K ﹤0.01% 10359
2020
Q3 		$124K Buy
25,500
+15,100
+145% +$98.7K ﹤0.01% 9138
2020
Q2 		$51K Buy
+10,400
New +$47.9K ﹤0.01% 9290

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors's AQST Position: Q1 2026 in Review

Citadel Advisors reduced its Aquestive Therapeutics (AQST) stake by 1% in Q1 2026, selling an estimated $23.3K and leaving 565,203 shares worth $2.35M. The position accounts for ﹤0.01% of the portfolio, ranked #5751.

Citadel Advisors first reported a position in AQST in Q3 2018 and has held it in 24 quarters since. The position peaked at $4.34M in Q3 2024. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Citadel Advisors held 565,203 shares of Aquestive Therapeutics worth $2.35M as of Q1 2026.
  • Citadel Advisors sold 5,742 Aquestive Therapeutics shares in Q1 2026, an estimated $23.3K.
  • Aquestive Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5751 holding.
  • Citadel Advisors first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 24 quarters since.
  • Citadel Advisors's Aquestive Therapeutics position peaked at $4.34M in Q3 2024.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.